pd treatment group Search Results


anti-pd-1 mabs  (McKesson Corp)
90
McKesson Corp anti-pd-1 mabs
Anti Pd 1 Mabs, supplied by McKesson Corp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pd+treatment+group/anti+pd+1+mabs/pmc11613493-41-20-23
Average 90 stars, based on 1 article reviews
anti-pd-1 mabs - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
carboplatin  (McKesson Corp)
90
McKesson Corp carboplatin
Carboplatin, supplied by McKesson Corp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pd+treatment+group/carboplatin/pm39623404-50-20-23
Average 90 stars, based on 1 article reviews
carboplatin - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
invivomab anti pd 1  (Bio X Cell)
99
Bio X Cell invivomab anti pd 1
Invivomab Anti Pd 1, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pd+treatment+group/InVivoMAb+anti-mouse+PD-1/pm40976049-112-7-14
Average 99 stars, based on 1 article reviews
invivomab anti pd 1 - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier
serplulimab  (ASTRUM IT GmbH)
90
ASTRUM IT GmbH serplulimab
Immune checkpoint (IC) blockade and related clinical trials in SCLC. PD-L1 expressed on cancer cells interacts with PD-1 on T cells to activate exhaustion and suppression pathways in T cells. Immune checkpoint inhibitors (ICIs) that impede this interaction have been developed and evaluated in different clinical trials for treatment-naïve ES-SCLC, combined with standard-of-care chemotherapy. The clinical trials include IMpower133 evaluating Atezolizumab (anti-PD-L1 antibody), CASPIAN evaluating Durvalumab (anti-PD-L1 antibody), Keynote-604 evaluating Pembrolizumab (anti-PD-1 antibody), CAPSTONE-1 evaluating Adebrelimab (anti-PD-L1 antibody) and ASTRUM-005 evaluating <t>Serplulimab</t> (anti-PD-1 antibody). [Created with BioRender.com (accessed on 18 February 2024)].
Serplulimab, supplied by ASTRUM IT GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pd+treatment+group/serplulimab/pmc10931009-12-8-3
Average 90 stars, based on 1 article reviews
serplulimab - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
anti pd 1  (Bio X Cell)
96
Bio X Cell anti pd 1
Immune checkpoint (IC) blockade and related clinical trials in SCLC. PD-L1 expressed on cancer cells interacts with PD-1 on T cells to activate exhaustion and suppression pathways in T cells. Immune checkpoint inhibitors (ICIs) that impede this interaction have been developed and evaluated in different clinical trials for treatment-naïve ES-SCLC, combined with standard-of-care chemotherapy. The clinical trials include IMpower133 evaluating Atezolizumab (anti-PD-L1 antibody), CASPIAN evaluating Durvalumab (anti-PD-L1 antibody), Keynote-604 evaluating Pembrolizumab (anti-PD-1 antibody), CAPSTONE-1 evaluating Adebrelimab (anti-PD-L1 antibody) and ASTRUM-005 evaluating <t>Serplulimab</t> (anti-PD-1 antibody). [Created with BioRender.com (accessed on 18 February 2024)].
Anti Pd 1, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pd+treatment+group/InVivoMAb+anti-mouse+PD-1/ppr0899011-236-9-13
Average 96 stars, based on 1 article reviews
anti pd 1 - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier
io360 panel pd l1 gene expression across various treatment groups  (Bruker Corporation)
96
Bruker Corporation io360 panel pd l1 gene expression across various treatment groups
Immune checkpoint (IC) blockade and related clinical trials in SCLC. PD-L1 expressed on cancer cells interacts with PD-1 on T cells to activate exhaustion and suppression pathways in T cells. Immune checkpoint inhibitors (ICIs) that impede this interaction have been developed and evaluated in different clinical trials for treatment-naïve ES-SCLC, combined with standard-of-care chemotherapy. The clinical trials include IMpower133 evaluating Atezolizumab (anti-PD-L1 antibody), CASPIAN evaluating Durvalumab (anti-PD-L1 antibody), Keynote-604 evaluating Pembrolizumab (anti-PD-1 antibody), CAPSTONE-1 evaluating Adebrelimab (anti-PD-L1 antibody) and ASTRUM-005 evaluating <t>Serplulimab</t> (anti-PD-1 antibody). [Created with BioRender.com (accessed on 18 February 2024)].
Io360 Panel Pd L1 Gene Expression Across Various Treatment Groups, supplied by Bruker Corporation, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pd+treatment+group/LC-NMR/10__1158_slash_1535___7163__mct___24___0379-384-8-7
Average 96 stars, based on 1 article reviews
io360 panel pd l1 gene expression across various treatment groups - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier
pbs  (Bio X Cell)
97
Bio X Cell pbs
Immune checkpoint (IC) blockade and related clinical trials in SCLC. PD-L1 expressed on cancer cells interacts with PD-1 on T cells to activate exhaustion and suppression pathways in T cells. Immune checkpoint inhibitors (ICIs) that impede this interaction have been developed and evaluated in different clinical trials for treatment-naïve ES-SCLC, combined with standard-of-care chemotherapy. The clinical trials include IMpower133 evaluating Atezolizumab (anti-PD-L1 antibody), CASPIAN evaluating Durvalumab (anti-PD-L1 antibody), Keynote-604 evaluating Pembrolizumab (anti-PD-1 antibody), CAPSTONE-1 evaluating Adebrelimab (anti-PD-L1 antibody) and ASTRUM-005 evaluating <t>Serplulimab</t> (anti-PD-1 antibody). [Created with BioRender.com (accessed on 18 February 2024)].
Pbs, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pd+treatment+group/InVivoMAb+anti-mouse+PD-L1/pm37591954-55-19-20
Average 97 stars, based on 1 article reviews
pbs - by Bioz Stars, 2026-09
97/100 stars
  Buy from Supplier
combination therapy group  (Bio X Cell)
93
Bio X Cell combination therapy group
Immune checkpoint (IC) blockade and related clinical trials in SCLC. PD-L1 expressed on cancer cells interacts with PD-1 on T cells to activate exhaustion and suppression pathways in T cells. Immune checkpoint inhibitors (ICIs) that impede this interaction have been developed and evaluated in different clinical trials for treatment-naïve ES-SCLC, combined with standard-of-care chemotherapy. The clinical trials include IMpower133 evaluating Atezolizumab (anti-PD-L1 antibody), CASPIAN evaluating Durvalumab (anti-PD-L1 antibody), Keynote-604 evaluating Pembrolizumab (anti-PD-1 antibody), CAPSTONE-1 evaluating Adebrelimab (anti-PD-L1 antibody) and ASTRUM-005 evaluating <t>Serplulimab</t> (anti-PD-1 antibody). [Created with BioRender.com (accessed on 18 February 2024)].
Combination Therapy Group, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pd+treatment+group/RecombiMAb+anti-mouse+PD-1/10__1080_slash_2162402x__2025__2539442-63-27-38
Average 93 stars, based on 1 article reviews
combination therapy group - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
cell-pd + alloc-dox  (Alloc Modulo LTD)
90
Alloc Modulo LTD cell-pd + alloc-dox
Immune checkpoint (IC) blockade and related clinical trials in SCLC. PD-L1 expressed on cancer cells interacts with PD-1 on T cells to activate exhaustion and suppression pathways in T cells. Immune checkpoint inhibitors (ICIs) that impede this interaction have been developed and evaluated in different clinical trials for treatment-naïve ES-SCLC, combined with standard-of-care chemotherapy. The clinical trials include IMpower133 evaluating Atezolizumab (anti-PD-L1 antibody), CASPIAN evaluating Durvalumab (anti-PD-L1 antibody), Keynote-604 evaluating Pembrolizumab (anti-PD-1 antibody), CAPSTONE-1 evaluating Adebrelimab (anti-PD-L1 antibody) and ASTRUM-005 evaluating <t>Serplulimab</t> (anti-PD-1 antibody). [Created with BioRender.com (accessed on 18 February 2024)].
Cell Pd + Alloc Dox, supplied by Alloc Modulo LTD, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pd+treatment+group/cell+pd+++alloc+dox/pm38445625-96-6-8
Average 90 stars, based on 1 article reviews
cell-pd + alloc-dox - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


Immune checkpoint (IC) blockade and related clinical trials in SCLC. PD-L1 expressed on cancer cells interacts with PD-1 on T cells to activate exhaustion and suppression pathways in T cells. Immune checkpoint inhibitors (ICIs) that impede this interaction have been developed and evaluated in different clinical trials for treatment-naïve ES-SCLC, combined with standard-of-care chemotherapy. The clinical trials include IMpower133 evaluating Atezolizumab (anti-PD-L1 antibody), CASPIAN evaluating Durvalumab (anti-PD-L1 antibody), Keynote-604 evaluating Pembrolizumab (anti-PD-1 antibody), CAPSTONE-1 evaluating Adebrelimab (anti-PD-L1 antibody) and ASTRUM-005 evaluating Serplulimab (anti-PD-1 antibody). [Created with BioRender.com (accessed on 18 February 2024)].

Journal: Cancers

Article Title: Promises of Protein Kinase Inhibitors in Recalcitrant Small-Cell Lung Cancer: Recent Scenario and Future Possibilities

doi: 10.3390/cancers16050963

Figure Lengend Snippet: Immune checkpoint (IC) blockade and related clinical trials in SCLC. PD-L1 expressed on cancer cells interacts with PD-1 on T cells to activate exhaustion and suppression pathways in T cells. Immune checkpoint inhibitors (ICIs) that impede this interaction have been developed and evaluated in different clinical trials for treatment-naïve ES-SCLC, combined with standard-of-care chemotherapy. The clinical trials include IMpower133 evaluating Atezolizumab (anti-PD-L1 antibody), CASPIAN evaluating Durvalumab (anti-PD-L1 antibody), Keynote-604 evaluating Pembrolizumab (anti-PD-1 antibody), CAPSTONE-1 evaluating Adebrelimab (anti-PD-L1 antibody) and ASTRUM-005 evaluating Serplulimab (anti-PD-1 antibody). [Created with BioRender.com (accessed on 18 February 2024)].

Article Snippet: 5 , NCT04063163 (ASTRUM-005) , Group I (Treatment): Serplulimab (PD-1 inhibitor) + carboplatin-etoposide (C/E) chemotherapy Group II (Control): Placebo + C/E chemotherapy , OS , OS: Group I: 15.4 months Group II: 10.9 months , [ ] .

Techniques: Clinical Proteomics

List of clinical trials in phase III for treatment-naïve ES-SCLC patients.

Journal: Cancers

Article Title: Promises of Protein Kinase Inhibitors in Recalcitrant Small-Cell Lung Cancer: Recent Scenario and Future Possibilities

doi: 10.3390/cancers16050963

Figure Lengend Snippet: List of clinical trials in phase III for treatment-naïve ES-SCLC patients.

Article Snippet: 5 , NCT04063163 (ASTRUM-005) , Group I (Treatment): Serplulimab (PD-1 inhibitor) + carboplatin-etoposide (C/E) chemotherapy Group II (Control): Placebo + C/E chemotherapy , OS , OS: Group I: 15.4 months Group II: 10.9 months , [ ] .

Techniques: Clinical Proteomics, Control